These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 8205134)
1. Development of radioimmunoassay for the novel platelet activating factor receptor antagonist, E6123, and its application to pharmacokinetics in laboratory animals. Kusano K; Tadano K; Tanaka S; Kagei Y; Ueda M; Miyazawa S; Abe Y; Ida S; Yuzuriha T Biol Pharm Bull; 1994 Feb; 17(2):334-9. PubMed ID: 8205134 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of a new thienodiazepine platelet activating factor receptor antagonist (E6123) in laboratory animals. Is there a metabolic polymorphism in the rhesus monkey? Kusano K; Tanaka S; Abe Y; Ida S; Yuzuriha T Xenobiotica; 1993 Jun; 23(6):589-98. PubMed ID: 8212733 [TBL] [Abstract][Full Text] [Related]
3. Metabolic polymorphism of E6123 in rhesus monkey. Kusano K; Tanaka S; Ando T; Abe Y; Ida S; Yuzuriha T Xenobiotica; 1993 Jun; 23(6):599-608. PubMed ID: 8212734 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of a novel PAF antagonist E6123 on anaphylactic responses in passively and actively sensitized guinea pigs and passively sensitized mice. Sakuma Y; Muramoto K; Harada K; Katayama S; Tsunoda H; Katayama K Prostaglandins; 1991 Dec; 42(6):541-55. PubMed ID: 1801063 [TBL] [Abstract][Full Text] [Related]
7. Effects of a novel PAF antagonist, E6123, on PAF-induced biological responses. Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K Agents Actions Suppl; 1990; 31():251-4. PubMed ID: 2080757 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological effects of oral E6123, a novel PAF antagonist, on biological changes induced by PAF inhalation in guinea pigs. Sakuma Y; Tsunoda H; Shirato M; Katayama S; Yamatsu I; Katayama K Prostaglandins; 1991 Nov; 42(5):463-72. PubMed ID: 1763202 [TBL] [Abstract][Full Text] [Related]
9. Effects of a novel PAF antagonist, E6123, on passive anaphylaxis. Sakuma Y; Tsunoda H; Katayama S; Harada K; Obaishi H; Shirato M; Yamada K; Miyazawa S; Okano K; Machida Y Agents Actions Suppl; 1990; 31():255-8. PubMed ID: 2080758 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331 [TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal physiology-regulated dogs: utilization of a bioavailability study of a new thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]-diazepine, an antagonist of platelet-activating factor, and its preparations. Sagara K; Yamada I; Kawazoe Y; Mizuta H; Shibata M Biol Pharm Bull; 1994 Jan; 17(1):117-20. PubMed ID: 8148798 [TBL] [Abstract][Full Text] [Related]
12. Brotizolam radioimmunoassay: development, evaluation, and application to human plasma samples. Bechtel WD; Weber KH J Pharm Sci; 1985 Dec; 74(12):1265-9. PubMed ID: 4087192 [TBL] [Abstract][Full Text] [Related]
13. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188 [TBL] [Abstract][Full Text] [Related]
14. Radioimmunoassay for DS-4574, an antiallergic agent: development, evaluation, and application to human plasma samples. Murayama N; Nakaoka M; Nomura H; Hakusui H J Pharm Sci; 1994 Nov; 83(11):1574-7. PubMed ID: 7891277 [TBL] [Abstract][Full Text] [Related]
16. Aprikalim: radioimmunoassay and pharmacokinetic studies in mouse, monkey, and dog. Chevalier P; Rouillard C; Montay G; Frydman A J Pharm Sci; 1994 Mar; 83(3):372-8. PubMed ID: 8207684 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation. Ring PC; Seldon PM; Barnes PJ; Giembycz MA Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man. Brecht HM; Adamus WS; Heuer HO; Birke FW; Kempe ER Arzneimittelforschung; 1991 Jan; 41(1):51-9. PubMed ID: 1646613 [TBL] [Abstract][Full Text] [Related]
19. Structure-activity studies on triazolothienodiazepine derivatives as platelet-activating factor antagonists. Miyazawa S; Okano K; Shimomura N; Clark RS; Kawahara T; Asano O; Yoshimura H; Miyamoto M; Sakuma Y; Muramoto K Chem Pharm Bull (Tokyo); 1991 Dec; 39(12):3215-20. PubMed ID: 1814614 [TBL] [Abstract][Full Text] [Related]
20. Determination of the anti-platelet-activating factor BN-50727 and its metabolites in human plasma by high-performance liquid chromatography-solid-phase extraction. Pruñonosa J; Parera L; Peraire C; Pla F; Lavergne O; Obach R J Chromatogr B Biomed Appl; 1995 Jun; 668(2):281-90. PubMed ID: 7581863 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]